Lantern Pharma Inc.
Lantern Pharma Inc. is listed today as Lantern Pharma Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2019 | $2 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Lantern Pharma Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2019).
SEC Form D · Mar 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2019
That is all the official record says: Lantern Pharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Lantern Pharma Inc. are on record.
Investors#
19 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| BIOS Advisors GP, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| BIOS Capital Management, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Bios Equity Partners II, LP | Private equity | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Bios Equity Partners, LP | Private equity | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| BIOS Fund II, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| BIOS Fund II NT, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| BIOS Fund II QP, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| BIOS Fund I, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| BIOS Fund I QP, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| BP Directors, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cavu Advisors, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cavu Management, LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| D. Jeffrey Keyser | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2020) | SEC Form 3 |
| GPG LPI Investment, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Green Park & Golf Ventures II, LLC | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Green Park & Golf Ventures, LLC | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Health Wildcatters Fund II, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Health Wildcatters, LLC | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Lantern 3-19 Investment, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 5 investors.
Largest shareholders today
Institutions holding Lantern Pharma Inc. shares, as of Sep 30, 2026.
- Armistice Capital, LLC$1 M8.10%
- Empery Asset Management, LP$1 M4.25%
- CM Management, LLC$1 M3.91%
- Vanguard Capital Management LLC$0 M3.29%
- Renaissance Technologies LLC$0 M2.88%
- BIOS Capital Management, LP$0 M1.85%
- Two Sigma Investments, LP$0 M1.11%
- UBS Group AG$0 M0.98%
- Geode Capital Management, LLC$0 M0.80%
- Vanguard Fiduciary Trust Co$0 M0.39%
- Westside Investment Management, Inc.$0 M0.37%
- Susquehanna International Group, LLP$0 M0.31%
- HRT Financial LP$0 M0.24%
- NewEdge Advisors, LLC$0 M0.21%
- DAVENPORT & Co LLC$0 M0.19%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Panna Sharma | Executive officer | Mar 2019 |
| Arunkumar Asaithambi | Director | Mar 2019 |
| David Silberstein | Director | Mar 2019 |
| Donald Keyser | Director | Mar 2019 |
| John Fucci | Director | Mar 2019 |
| Panna Sharma | Director | Mar 2019 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.